Old Web
English
Sign In
Acemap
>
authorDetail
>
Karin Weigang-Koehler
Karin Weigang-Koehler
Medicine
Gemcitabine
Pathology
Biomarker (medicine)
Internal medicine
4
Papers
2001
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients (pts) with advanced solid tumors.
2017
Journal of Clinical Oncology
Sandrine Faivre
Anthony J. Olszanski
Karin Weigang-Koehler
Hanno Riess
Guangbin Peng
Sophie Callies
Karim A. Benhadji
Eric Raymond
Show All
Source
Cite
Save
Citations (4)
MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy.
2012
Journal of Clinical Oncology
Michael Staehler
L. Bergmann
Viktor Grünwald
Torsten Huschke
Ulrich Keilholz
Carsten Ohlmann
Michael Stöckle
Karin Weigang-Koehler
Kirsten Hauswald
Felix Schaller
Luise Strassl
Kerstin Junker
Show All
Source
Cite
Save
Citations (1)
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial
2007
JAMA
Helmut Oettle
Stefan Post
Peter Neuhaus
Klaus Gellert
Jan M. Langrehr
K. Ridwelski
H. Schramm
J. Fahlke
Carl Zuelke
Christof Burkart
Klaus Gutberlet
E. Kettner
Harald Schmalenberg
Karin Weigang-Koehler
Wolf Otto Bechstein
Marco Niedergethmann
Ingo G.H. Schmidt-Wolf
L. Roll
Bernd Doerken
Hanno Riess
Show All
Source
Cite
Save
Citations (1990)
1